Amgen Inc.
Amgen Reports Strong Second Quarter 2025 Financial Results
Summary
Amgen Inc. reported a strong financial performance for the second quarter of 2025, with total revenues increasing by 9% to $9.2 billion. GAAP earnings per share (EPS) rose significantly by 92% from $1.38 to $2.65. Non-GAAP EPS also increased by 21% from $4.97 to $6.02, driven by higher revenues. The company generated $1.9 billion in free cash flow, despite higher capital expenditures. Product sales saw robust growth, with fifteen products achieving at least double-digit sales growth, including Repatha and EVENITY. Further, Amgen provided updates on its pipeline, with several Phase 3 studies showing promising results.
Profitelligence Alerts
Get alerts for AMGN
Be first to know when Amgen Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Amgen Inc.
Amgen Inc. is a leading biotechnology company focused on the discovery, development, manufacturing, and marketing of human therapeutics. Established in 1980 and headquartered in Thousand Oaks, California, Amgen is recognized for pioneering biologic treatments and having a robust pipeline that targets critical areas like oncology, cardiovascular, and nephrology. The company has harnessed advanced technology platforms and deep scientific expertise to deliver innovative medicines such as Neulasta, Enbrel, and Prolia, which are significant players in the health care sector. Amgen serves markets globally, impacting the biotech industry by transforming the ways diseases are treated. Its investment in state-of-the-art manufacturing facilities and research makes it a significant entity in the pharmaceutical landscape, contributing to long-term health care solutions.
Official SEC Documents
Advertisement